CURRICULUM VITAE

June 21, 2017

EDWARD THOMAS MORGAN, PH.D.

PROFESSOR OF PHARMACOLOGY EMORY UNIVERSITY SCHOOL OF MEDICINE

DATE AND PLACE OF BIRTH: December 13, 1954; Millport, Scotland

<u>ADDRESS</u>: Department of Pharmacology 3889 Lee Ridge Way

Emory University, Atlanta GA 30322 Lilburn, GA 30047 (404) 727-5986 (770) 564-9512

NATIONALITY: U.S. citizen, British National.

EDUCATION:

1976 B.Sc (Pharmacology) Upper Second Class Honours

University of Glasgow, Scotland

1979 Ph.D. (Pharmacology) University of Glasgow, Scotland. Thesis title

"Ethanol: Its effects on hepatic microsomal drug metabolism".

Advisors: Dr. G. Powis, Dr. P. Skett

PROFESSIONAL APPOINTMENTS:

1979-1982 Postdoctoral Scholar, Department of Biological Chemistry, University

of Michigan, Ann Arbor, MI (with Dr. M.J. Coon).

1982-1986 Visiting Scientist Fellow, Department of Medical Nutrition,

Karolinska Institute, Stockholm, Sweden (with Prof. J.-Å. Gustafsson)

1986-1992 Assistant Professor, Department of Pharmacology

Emory University, Atlanta, GA

1992-1999 Associate Professor, Department of Pharmacology,

Emory University

1999-present Professor, Department of Pharmacology, Emory University

1995-present Winship Cancer Center, Drug Discovery and Development Division,

Emory University

RESEARCH INTERESTS:

Regulation of cytochrome P450 and other drug metabolizing

enzymes; Nitric oxide signaling; protein degradation

TEACHING ACTIVITY:

1982-1986 Lecturer in Graduate and Undergraduate Courses in Biochemical

Toxicology, Karolinska Institute, Stockholm, Sweden

1987-2007 Lecturer in BAHS 501 - Allied Health Pharmacology, Emory

University. 3-4 hr/ year

1987-present Lecturer in IBS 531 Introduction to Pharmacology (graduate), Emory

University. 4hr/year

1987-2006 Lecturer in MEDI 640 - Medical Pharmacology, Emory University, 6-7

hr/year

1989-1999	Course Director and Lecturer, IBS 740 - graduate course in Molecular Toxicology, Emory University, 9 lecture hr/year
1989	Lecturer in Introductory Graduate Biochemistry, Emory University, 1 hr
1991	Lecturer in Introductory Environmental and Occupational Toxicology, School of Public Health, Emory University, 2 hr
1994-97	Course Director, Graduate course in Principles and Approaches to Pharmacology, IBS 531 Emory University
1994	Co-director, Graduate Seminar PPS 597r
2000-present	Lecturer in IBS 740- Molecular Toxicology, 3-4 hr/year
2000-present	Course Director and lecturer, IBS 536 - Graduate Course in Drug Metabolism and Toxicology, Emory University. 10-12 lecture hr/year
2007-present	Lectures and small group sessions in Foundations of Medicine, Emory University, 7-8 hr/year
2008-present	Lectures in BAHS 504 - Introduction to Pharmacology for Anesthesiology Assistant, Emory University, 4-5 hr/year

SERVICE:

Emory University

1988-2000	Committee for Medical Student Research (Chair, 1992-2000)
June 1, 1988	Medical Curriculum Retreat
1992-95	Committee on Appointments, Promotions and Tenure, Medical School
1990	University Research Committee, Ad Hoc Reviewer
1989-1990	Coordinator for move of Pharmacology Department
1989-1992	Executive Committee, Graduate Program in Biochemistry and Molecular Biology
1990-1994	Director of Graduate Studies, Biochemistry and Molecular Biology Program
1993-1996	Executive Committee, Graduate Program in Physiological and Pharmacological Sciences
1994-1996	Director of Graduate Studies, Program in Physiological and Pharmacological Sciences
1996-1999	Director of Graduate Studies, Program in Molecular Therapeutics and Toxicology
1999-2010	Director, Graduate Program in Molecular & Systems Pharmacology
2010-2011	Co-Director, Graduate Program in Molecular & Systems Pharmacology
1990-1994	Student Teaching Assignment Committee, Graduate Division of

	Biological and Biomedical Sciences (Chair, 1991-94)
1994-1996	Graduate Teaching Award Committee, Graduate Division of Biological and Biomedical Sciences
1994-1997	Graduate School Executive Committee (Faculty Chair, 1996-97)
1997	Medical School Strategic Planning Subcommittee on Research Infrastructure
1999	Medical School Research Committee, LCME Accreditation
1999-2002	Committee on Appointments, Promotions and Tenure, Medical School
1999-2000	Office of Research and Office of Sponsored Programs Advisory Committee
2000	Faculty Development Workshop
2000-2001	Medical School Admissions Committee, Associate Member
2001-2009	Medical School Admissions Committee, Member
2004	Review panel, Center For AIDS Research Developmental Core Grants
2006	Foundations of Medicine Subcommittee, Medical School Curriculum Revision
2007	Institutional Settings Subcommittee, LCME accreditation
2010	Institutional Review and Investigation Committee (Responsible Conduct of Research)
2012-2014	Bobby Jones Scholarship Review Committee
2012-present	Chair of the Symposium Committee, Emory University STEM Research and Career Symposium
2013- present	Graduate Coordinator, Emory Initiative for Maximizing Student Development (IMSD)
2013- present	Reviewer, Emory Conference Center Subvention Fund
2013	Strategic Planning Committee for Undergraduate Medical Education
2013-2015	Online Masters Development Committee, Department of Pharmacology
2013-2016	School of Medicine Curriculum Committee, Program Evaluation and Foundations subcommittees
2014-present	Director, Department of Pharmacology Research Internship Program
2014-2019	Bobby Jones Program Advisory Committee
2015-2018	Dean's Faculty Advisory committee, School of Medicine
2015-2018	Scientific Integrity Committee, School of Medicine

Extramural

Professional Societies	
1993	Chair, Nominating Committee, Drug Metabolism Division of ASPET
1998-2001	Program Committee, ASPET
1998	Selection Committee, Bernard Brodie Award(ASPET)
1998-2001	Chair-Elect, Chair and Past-Chair, Drug Metabolism Division of ASPET
2003-2006	Councillor, Drug Metabolism Division of ASPET
2005-2010	Board of Publications Trustees, ASPET
1998-2001	Exhibits Committee, International Society for the Study of Xenobiotics (ISSX)
2006-2012	Publications and Communications Committee, FASEB
2006-2010	Julius Axelrod Award Committee, ASPET
2007- 2009	Executive Committee, Systems and Integrative Pharmacology Division of ASPET
2008-2012	Scientific Affairs Committee, ISSX
2011-2014	Secretary/Treasurer (Elect, Current and Past) ASPET
2014-	Finance committee, ASPET
2014-	Treasurer, Section on Drug Metabolism and Drug Transport, International Union of Basic and Clinical Pharmacology (IUPHAR)
2015-2019	Bernard B. Brodie Award Committee, ASPET
2017-2018	President-Elect, ASPET
Editorial Boards	
1994-2012	Editorial Board member, Drug Metabolism and Disposition
1995-1999	Associate Editor, Molecular Pharmacology
2004-2006	Editorial Board member, Current Drug Metabolism
2007- 2012	Advisory Board to the Editor-in-Chief, <i>FASEB Journal</i> (Chair 2011-2012)
2009- 2016	Editorial Board member, The Biochemical Journal
2012-2018	Editor-in-Chief, Drug Metabolism and Disposition
2015-present	Founding member, Atlanta Society of Members
Symposium and mee	ting organization
April, 1991	Organizing Committee "Cytochrome P-450: Advances and Prospects" Satellite symposium of FASEB meeting.
1994	Organizer, ASPET Symposium on "Model Systems for the Study of

	Activity and Regulation of Hepatic Drug Metabolizing Enzymes", Experimental Biology 94, Anaheim, CA
1998	Organizer, ASPET Symposium on "Physiological and Pathophysiological Regulation of Cytochrome P450", Experimental Biology 98, San Francisco, CA
1999	Organizing Committee, North American meeting of the International Society for the Study of Xenobiotics - AmericanChemical Society/Division of Chemical Toxicology, Nashville, TN
1999	Co-organizer, Symposium on Regulation of Enzymes Involved in Biotransformation; Relevance of Animal Models to Humans. 9 th North American ISSX Meeting, Nashville, TN October 1999
2001	Organizer, ASPET Symposium on "Cytochrome P450 as a Source and a Target of Nitric Oxide", Experimental Biology 2001, Orlando, FL
2007	Organizer, ASPET Symposium on "Regulation of Drug Metabolizing Enzymes and Transporters in Inflammatory Disease States: a symposium in honor of the career of Dr. Kenneth Renton", Experimental Biology 07, Washington, DC.
2011	Co-Organizer, ASPET Symposium on "Drug Metabolism and Action in Pathophysiological Conditions", Experimental Biology 2011, Washington, DC.
2011	Chair of the Meeting Organizing Committee, 17 th North American meeting of ISSX, Atlanta GA October 16-20, 2011
2012-2013	Organizing Committee, 10 th International meeting of ISSX, Toronto Canada. September 30 - October 3, 2013
2013-2014	Scientific Advisory Board, 20 th International Microsomes and Drug Oxidations Meeting, Stuttgart, Germany. May 18-22, 2014
2014-2015	International Advisory Board, 13 th European meeting of ISSX, Glasgow, Scotland June 2015
2015	Co-organizer, Symposium on Inflammation: Effects on Drug Metabolism and Disease Aetiology. 13 th European ISSX meeting, Glasgow UK.
2016	Co-Chair, ASPET Symposium: Hear It From the Editors: Navigating the Course Through Journal Submission and Publication. Experimental Biology 2016, San Diego, CA. April 2016.
2015 - 2016	Meeting Advisory Committee, Microsomes and Drug Oxidations Symposium, Davis, CA October 2106
2016	Co-Chair, Symposium on The Microbiome and Drug Metabolism. Microsomes and Drug Oxidations Symposium, Davis, CA October 2106
2017	Organizer and Chair, ASPET Symposium on "Physiological Regulation of Drug Metabolism and Transport", Experimental Biology 2017, Chicago, IL

Ad Hoc Manuscript Reviews:

Archives of Biochemistry and Biophysics J. Gastroenterol. Hepatol.

Biochemical Pharmacology Journal of Molecular Endocrinology

Biochemistry Journal of Neurochemistry

Biochimica et Biophysica Acta Journal of Nutrition

British Journal of Pharmacology J. Pharmacol. Exp.Therap.

Chemical Research in Toxicology Hepatology Endocrinology Life Sciences

Proc. Natl. Acad. Sci. U.S.A. Eur. J. Clin. Pharmacol.

Free Radicals in Biology and Medicine Science

Gastroenterology Toxicol. and Applied Pharmacology

Journal of Clinical Investigation **Toxicology Letters**

Journal of Biological Chemistry Xenobiotica

Grant Review Panels

2002-2003 Member, PHRA Study Section, National Institutes of Health 2004-2006 Member, XNDA Study Section, National Institutes of Health

2010-2012 Member, College of CSR Reviewers, National Institutes of Health

Ad Hoc grant reviews

1992	Louisiana State University Research Grants
1993	American Cancer Society
1998	Louisiana Board of Regents Support Fund
1998	U.SIsraeli Binational Science Foundation
1998-2001	Vanderbilt University Toxicology Center seed grants
2001	NIEHS Special Emphasis Panel, Advanced Research Cooperation in Environmental Health Sciences (ARCH) ZES1-JPM-B-AR
2002	PHRA Study Section, National Institutes of Health
2005,2006	MBPP Study Section, National Institutes of Health
2005	MBRS-SCORE proposals, Morehouse School of Medicine
2007	XNDA Study Section, National Institutes of Health
2007	HTSS Study Section, National Institutes of Health

NIH Special Emphasis Panel on Developmental Pharmacology 2008-2009

ZRG1 CB-L 50 (Chair, 2009)

2008 Kansas INBRE Pilot grant program

NIEHS P30 Center Review Committee ZES1-LKB-G-E9 2009

2010 NIH Transformative grant SEP ZRG1-BCMB-A51

2010 NIEHS Superfund P42 grant review panel ZES1 SET-V 04

2010-12 Member, College of CSR reviewers

2011 ZRG1 DKUS-C (40) P - Program Project (Chair)

2012 ZRG1 DKUS-D (03) - SEP - Chair

2014	ZRG1 DKUS-C (04) M
2015	ZRG1 DKUS C (52) (Chair)
2016	ZRG1 DKUS C (82)
Education	
2005-2006	Pharmacology Test Committee, National Board of Medical Examin
2005-2006	United States Medical Licensing Examination Step I Test Material Development Committee for Pharmacology
Advisory Boards	
2007- 2008	External Advisory Board, University of Texas Medical Branch NIEHS Center

SCHOLARSHIPS AND AWARDS:

1976-1978	Talbot Crosbie Scholarship, Medical Faculty of the University of Glasgow
1978-1979	Gardiner Scholarship, Medical Faculty of the University of Glasgow
1982-1984	Visiting Scientist Fellowship, Swedish Medical Research Council
1984-1986	Swedish Work Health Fund
1987-1989	Faculty Development Award, Pharmaceutical Manufacturer's Association Foundation
2004	Teaching Excellence Award, Department of Pharmacology, Emory University
2010	The MSP graduate program at Emory University established the Edward T. Morgan Award for outstanding service and leadership by an MSP student
2010-2013	Georgia Cancer Coalition Distinguished Cancer Scholar
2013-2015	Georgia Research Alliance Distinguished Cancer Scientist
2016	Dean's Teaching Award, Emory University School of Medicine

RESEARCH SUPPORT

Current	All amounts are Direct Costs	
2014-2018	2R-01GM069971-09 National Institute of General Medical Sciences "Nitric Oxide Regulation of Human CYP Enzymes" 9/1/14 – 8/31/18 \$997,710 entire project period (E. Morgan, PI),	
2013-2017	1P30ES019776-01A1 National Institute of Environmental Health Sciences "HERCULES: Health and Exposome Research Center at Emory" 4/1/13-3/31/17. \$900,000 in year 4. Role: Pilot Project Core Director (G. Miller, PI).	
2013-2016	R25 GM099644-01A1 National Institute of General Medical Sciences "Emory Initiative for Maximizing Student Development" 9/1/13-8/31/16 K. Wilkinson (PD/PI); P. Marsteller (MPI). \$1,140,000 yearly. Role: Asst.	

Director and Graduate Coordinator

Pending	
2013-2016	R25 GM099644-04A1 National Institute of General Medical Sciences "Emory Initiative for Maximizing Student Development" 9/1/13-8/31/16 K. Wilkinson (PD/PI); P. Marsteller , E. Morgan (MPI). \$1,054,000 yearly. Role: MPI and Graduate Coordinator. Status: Received an impact score of 37.
Completed	
1986-1988	Biomedical Research Support Grant. For "Hormonal Regulation of Expression of Sexually Differentiated Hepatic Isozymes of Cytochrome P-450." 7/1/86-6/30/88. \$14,700. (E. Morgan, PI)
1987-1989	Faculty Development Award, Pharmaceutical Manufacturer's Association Foundation. 7/1/87-6/30/89. \$50,000. (E. Morgan, PI)
1987-1988	Research Starter Grant, Pharmaceutical Manufacturer's Association Foundation. For "Growth Hormone Regulation of Sexually Differentiated Hepatic Isozymes of Cytochrome P-450." 1/1/87-12/31/88. \$20,000. (E. Morgan, PI)
1987-1988	Grant in Aid, American Heart Association, Georgia Affiliate. For "Altered Sex-dependent Hepatic Function in Diabetes Mellitus." 7/1/87-6/30/88. \$24,786. (E. Morgan, PI)
1988-1993	R29DK39968. National Institute of Diabetes and Digestive and Kidney Diseases, for "Growth Hormone Regulation of Hepatic Gene Expression" 5/1/88-4/30/93. \$338,157. (E. Morgan, PI)
1992-2005	R01GM46897 National Institute of General Medical Sciences. For "Suppression of P450 Genes by Inflammatory Mediators" 2/5/1992-6/30/2005. \$2,107,742 (E. Morgan, PI)
1997-2000	R01GM46897 National Institute of General Medical Sciences. For "Suppression of P450 Genes by Inflammatory Mediators". Supplement 9/1/97-6/30/00. \$64,868 (E. Morgan, PI)
1995-97	1R55GM/OD 53093. National Institute of General Medical Sciences. Shannon Director's award. For "Nitric Oxide in Regulation of Hepatic Cytochrome P450". 09/01/95 - 01/31/97. \$80,000 total. (E. Morgan, PI)
1997-2001	1R01GM53093, National Institute of General Medical Sciences "Nitric Oxide in Regulation of Hepatic Cytochrome P450. 2/01/97 - 1/31/01. \$427,563. (E. Morgan, PI)
2002-2005	R01GM46897-10S1 National Institute of General Medical Sciences. For "Suppression of P450 Genes by Inflammatory Mediators". Supplement 05/01/2003-6/30/05. \$99,500 (E. Morgan, PI)
2004-2008	R01GM069971-04 National Institute of General Medical Sciences. For "Regulation of CYP Proteins by Reactive Nitrogen Species" 2/1/041/31/08. \$704,000 (E. Morgan, PI)
2006	R01GM069971-03S1 National Institute of General Medical Sciences. For "Regulation of CYP Proteins by Reactive Nitrogen Species" 6/1/2006-8/10/06. \$6,446 (E. Morgan, PI)

2008-2009	R01 DK072372-03S1 "Hepatic CYP Enzymes and Host-Pathogen Interactions" 1/1/08-8/31/09/09. \$88,463 (E. Morgan, PI)
2010-2014	2R01 DK072372-08 National Institute of Diabetes and Digestive and Kidney Diseases "Hepatic CYP Enzymes and Host-Pathogen Interactions" 3/20/10-2/28/14. \$1,104,000. (E. Morgan, PI) No cost extension to 1/31/15
2004-2013	5T32GM008602 National Institute of General Medical Sciences "Graduate Training in the Pharmacological Sciences" 7/1/01-6/30/17. \$255,192 direct costs yearly, supporting six graduate student stipends. Morgan PI since 2004. (E. Morgan, PI)
2009-2013	R01GM069971-08 National Institute of General Medical Sciences. "Regulation of CYP Proteins by Reactive Nitrogen Species" 7/15/095/31/13. \$865,476 (E. Morgan, PI). NCE until 5/31/14
2010-2015	Georgia Research Alliance. Distinguished Cancer Clinicians and Scholars Award. 7/1/10 – 6/30/15. \$150,000 direct costs yearly.

MEMBERSHIP OF PROFESSIONAL SOCIETIES:

American Society for Pharmacology and Experimental Therapeutics International Society for the Study of Xenobiotics The Biochemical Society (U.K.)

GRADUATE STUDENTS SUPERVISED AND CURRENT POSITIONS:

- Catriona MacGeoch, Ph.D. 1986 (Karolinska Institute) Research Associate, Imperial Cancer Institute, England
- Brian S. Donahue, M.D., Ph.D. 1990 (Emory University) Associate Professor, Director of Pediatric Cardiac Anesthesia, Vanderbilt University
- Anders Ström, Ph.D. 1994 (Karolinska Institute) Research Associate Professor, Biology and Biochemistry, University of Houston
- Sara Byers Roeper, M.S. 1994 (Emory University) High School Science Teacher, Loudon County Public Schools, GA,
- Marion Sewer, Ph.D 1998 (Emory University) Professor, U. California San Diego (deceased)
- Thomas Barclay, M.S. 1998 (Emory University) Director of Educational Technology at Cliff Valley School, Atlanta, GA
- Tong Li-Masters, Ph.D. 2001 (Emory University), M.D. 2005 (Medical College of Georgia). Physician, Wake Forest Baptist Med. Ctr.

$\frac{\textbf{GRADUATE STUDENT DOCTORAL THESIS COMMITTEE MEMBER FOR}}{(\textbf{Student, date graduated})}:$

,		Molecular and Systems Pharma	acology
Biochemistry & Molecular Biolog	ıy	Romesh Subramanian	2001
Xiaoqin Shan	1991	Michael Davis	2003
Krista Hamilton	1991	Aaron Robida	2004
Mary Kreck	1996	Kenneth Mandel	2005
Jennifer Freeman	1996	J. Scott McNally	2005
Jiang Liu	1997	Yvonne Nkabyo	2005
Biochemistry, Cell & Dev. Biolog	v	Douglas McMillin	2005
Yunfei Huang	y 2000	Erin Morrey	2006
Jing Chen	2000	Matthew Whalin	2007
Sing Onen	2001	Roddy O'Connor	2007
Nutrition and Health Sciences		Lucienne Ide	2007
Emma Patten	2001	Lisa Montoya (Cockrell)	2008
Mary Yeh	2007	Yanci Mannery	2010
Genetics and Molecular Biology		Anthony Lau	2010
Beth McConnell	1996	George Rogge	2010
	1000	Alicia Lyle	2010
Pharmacology		Sheena Brown	2011
K. Bradford Thomas	1994	Jonathan Havel	2013
Physiol. and Pharmacol. Science	s	Eric Armstrong	2014
Paula Samiec	1995	Rich Stanton	2016
Ward Kirlin	1996	Eric Salgado	
		Harrison Brown	
Molecular Therapeutics and Toxi		Biology, Georgia Inst of Techno	ology
Xiaofei Wang	1998	Eric Dammer	2008
Jiyang Cai	1999	2.10 2.11.11.01	

POSTDOCTORAL ASSOCIATES AND CURRENT POSITIONS:

1989-90	Kristina Wright, Ph.D (sabbatical), Associate Professor, Department of Biology, Georgia State University. Retired.
1991-93	Kenneth Bradford Thomas, Ph.D. Project Leader, GE Healthcare
1992-95	Jin-Qiang Chen, Ph.D. Molecular Application Scientist, Goldbelt Falcon LLC. Visiting Scholar, Johns Hopkins Bloomberg School of Public Health
1994	Karen Ching, M.D., Ph.D., Microbiologist, Centers for Disease Control (CDC)
1995-1997	Luc Ferrari, Pharm.D., Ph.D. (sabbatical) Associate Professor, School of Pharmacy, University of Nancy, France
1995-1999	Heinrich Iber, Ph.D., Software engineer, NCR.
1998-99	Saswata Bhadury, Ph.D. Software developer, BellSouth
1999-03	Po-Yung Cheng, Ph.D. Biostatistician, Battelle
2002-05	Chad Brommer, Ph.D. Biologist – Herbicides, BASF
2003-05	Terrilyn A Richardson, Ph.D., Associate Professor, Northeastern Ohio Medical University

2003-2006	Alison Aitken, Ph.D., Homemaker
2006-2007	Madhusudana Rao Chaluvadi, Ph.D., Pharmacologist, FDA
2008-2010	Ryan Kinloch, Ph.D., Public Health Analyst (Policy), Centers for Disease Control and Prevention
2004- 2011	Choon-myung Lee, Ph.D. Research Associate, Emory University
2007- 2013	Beatrice Nyagode, Ph.D., Pharmacovigilance Manager, Procter & Gamble Inc.
2010-2011	Haiyan Sun, Ph.D. (sabbatical). Associate Professor, Shenzhen Polytechnic, Shenzhen, PRC.
2010-2013	Shweta Tripathi, Ph.D., Research Assistant Professor, Tuskegee University
2011-2014	Matthew Merrell, Ph.D., Study Director, Southern Research Institute
2012-2013	Bang-Sub Lee, Ph.D. (Visiting Professor), Assistant Professor, Department of Human Movement Science, Seoul Women's University
2015-	Ji Won Park, Ph.D. current

<u>UNDERGRADUATES AND POSTBACCALAUREATE STUDENTS MENTORED</u>:

1988-89	Catherine Norman	
1991-92	Nikita Ferguson	
1993-95	Anna Borodovsky. PhD, Harvard U. Associate Director Alnylam Pharmaceuticals.	
2005-06	Tarik Smith	
2006-08	Christal Hembree Adams, Associate Clinical Lab Data Analyst at Q² Solutions	
2010-12	Petria Thompson. MD/PhD student at Vanderbilt Univerity	
2012-13	Bernard Scott. M.Sci. student in Chemistry at Georgia State University	
2013-14	Sylvie Mimche.	
2013	Roya Jahangardi	
2015	Andrea Amez	
2015-2016	Aria Byrd. PhD student in Toxicology, University of Kentucky	
2015	Tian Mi. BS/MS student in Cancer Biology, Emory University	
2016	Joan Cheng.	

INVITED RESEARCH SEMINARS AND LECTURES:

Department of Biological Chemistry, University of Michigan. February, 1986.

Department of Clinical Pharmacology, Karolinska Institute. June 1986.

Department of Medicine, Emory University. Grand Rounds: September, 1987.

Department of Pharmacology, Mayo Clinic. January, 1988.

Department of Biochemistry, Southwestern Medical School, June, 1988.

Pharmaceutical Manufacturer's Association Foundation. Annual Awardee's Meeting, Washington D.C. February, 1989.

Department of Pharmacology, Morehouse School of Medicine. April, 1989

Department of Foods and Nutrition, University of Georgia. May, 1990.

Department of Pharmacology, Louisiana State University Medical School. April 1992.

Department of Medical Nutrition, Karolinska Institute, Sweden. May, 1992

Division of Pharmacology and Experimental Therapeutics, University of Kentucky College of Pharmacy. October, 1992.

Department of Pharmacology and Toxicology, University of Arizona College of Pharmacy March. 1994.

Department of Physiology and Pharmacology, Oregon Health Sciences University. September, 1995.

Department of Chemical Biology, Rutgers University. September, 1996.

Pfizer Inc., Central Research Division. September, 1996.

Department of Biology, Berry College. September, 1996.

Department of Medical Biochemistry and Biophysics, Karolinska Institute. December 1996.

Department of Medical Biochemistry and Biophysics, Karolinska Institute. External faculty opponent in Ph.D dissertation defense by Niclas Tindberg. December 1996.

Curriculum in Toxicology, University of North Carolina. October 1997

Minority Biomedical Research Support Program, Spelman College. June 1998

Wadsworth Center, New York State Department of Health; and SUNY Albany, School of Public Health. November 1998.

Department of Pharmacology and Toxicology, University of Alabama at Birmingham. November 1998.

Department of Pharmacology, University of Montreal. September 1999.

Department of Biochemistry, University of Texas-Houston, February 2000

Joseph F. Williams Memorial Lecture, Department of Pharmacology and Therapeutics, University of South Florida, April 2000

Departments of Pharmacology and Biological Chemistry, University of Michigan, May 2000

Department of Medicinal Chemistry, University of Washington, May 2000

Department of Biological Sciences, Clark Atlanta University, March 2001

Research Infrastructure in Minority Institutions (RIMI) Program, Spelman College, June 2001

Center for Toxicology, Vanderbilt University, September 2002

MBRS Program, Morehouse School of Medicine, September 2002

Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, February 2005

Pfizer Inc., Groton. Pharmacokinetics, Dynamics and Metabolism Division, May 2006

Delaware Valley Drug Metabolism Group, March 2007

Fox Chase Cancer Center, March 2007

Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, April 2007

Department of Pharmacology, University of Toronto. Keynote Speaker, Visions in Pharmacology Symposium, May 2007

Pfizer Inc., St. Louis. Pharmacokinetics, Dynamics and Metabolism Division, May 2007

Department of Pharmacology, University of Houston. November 2007

Research Triangle Park Drug Metabolism Discussion Group, May 2008

FDA Center for Drug Evaluation and Research, Visiting Professor Lecture Series (VPLS) co-sponsored by the Office of Clinical Pharmacology and the Office of Executive Programs. October 2008.

Department of Pharmaceutical Sciences, University of Maryland, December 2008

Johnson & Johnson / Centocor, Raritan, NJ April 2010

Department of Pharmacology and Toxicology, University of Kentucky, April 2010

Boehringer-Ingelheim R&D, Ridgefield, CT, June 2010

Division of Clinical Pharmacology, Indiana University School of Medicine, May 2011

Department of Pharmaceutics, University of Pittsburgh, February 2012

Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, January 2013

Department of Pharmacology and Molecular Sciences, Johns Hopkins University, January 2013.

Linus Pauling Institute, Oregon State University, April 2013

Department of Pharmaceutics, University of Washington, March 2015

Department of Biopharmaceutical Sciences, University of Illinois-Chicago, September 2015

MARC and RISE programs, Winston-Salem State University, March 2016

Department of Biological Sciences, Clemson University, April 2016

Fudan University lecture series: The Advancement and Methodology for Molecular Mechanisms of Toxicology. Shanghai, China December 2016

PLATFORM AND SYMPOSIUM PRESENTATIONS:

Symposium on Relationships between Host-Defense and Drug Biotransformation. (Chair and speaker) FASEB meeting, Anaheim, CA. April 1992.

Gordon Conference on Drug Metabolism. Session on Cytochrome P450 regulation during host defense activation. July 1992.

Symposium on Model Systems for the Study of Activity and Regulation of Hepatic Drug

Metabolizing Enzymes. (Co-Chair and speaker) Experimental Biology 94, Anaheim, CA. April 1994.

Symposium on Inflammatory Effects and Drug-Metabolism/Drug Metabolizing Enzymes. 10th International Symposium on Microsomes and Drug Oxidations, Toronto, Canada. July 1994

Symposium on Drug Metabolism in Early Drug Development. North Jersey ACS Drug Metabolism Discussion Group. Somerset, New Jersey, September 1996

Symposium on Enzymatic Transformation of Xenobiotic Chemicals. Center in Molecular Toxicology, Vanderbilt University. April 1997

Symposium on Physiological and Pathophysiological Regulation of Cytochrome P450. Experimental Biology 98, San Francisco, CA. April, 1998.

Gordon Conference on Drug Metabolism. Session on Activities and Regulation of the CYP4A Subfamily. July 1999.

Symposium on Mechanisms of Inducible Expression of P450 genes. 11th International Conference on Cytochrome P450, Biochemistry, Biophysics and Molecular Biology. Sendai, Japan. August 1999.

Symposium on Regulation of Enzymes Involved in Biotransformation; Relevance of Animal Models to Humans. 9th North American ISSX Meeting, Nashville, TN October 1999

Symposium on Drug Metabolism and Toxicology: Summer meeting, British Pharmacology Society. Cardiff, Wales July 2000

Symposium on Inflammation and Drug Metabolism (Co-chair): VII World Conference on Clinical Pharmacology and Therapeutics. Florence, Italy. July, 2000

Symposium on Cytochrome P450 as a Source and a Target of Nitric Oxide. (Chair and speaker) Experimental Biology 01, Orlando, FL. March-April 2001

Symposium on Regulation of Cytochrome P450 Gene Expression: 9th International Congress of Toxicology. Brisbane, Australia, July 2001

Symposium on Transcriptional suppression of Cytochrome P450 Genes by Endogenous and Exogenous Chemicals. Experimental Biology 2003, San Diego, CA

Southeastern Pharmacology Society, Annual Meeting October 2003, Atlanta, GA

Joint meeting of the Southeastern Pharmacology Society and Southeastern Society of Toxicology, Nashville TN, October 2005.

Symposium on Infection, Inflammation and Immunity. 5th International Congress of Pathophysiology Beijing, China, June 2006

Symposium on Modulation of Xenobiotic Response by Nutritional and Inflammatory Factors. (Co-Chair and speaker) 14th North American ISSX Meeting. Rio Grande, Puerto Rico, October 2006

Symposium on Drug Metabolizing Enzymes and Disease Pathogenesis. 2006 AAPS Annual Meeting. San Antonio, TX. November 2006.

Symposium on Regulation of Drug Metabolizing Enzymes and Transporters in Inflammatory Disease States: a symposium in honor of the career of Dr. Kenneth Renton (Chair and speaker). Experimental Biology 07, Washington DC, April 2007.

Biotransformation Workshop: Emerging Issues Related to Large Molecule Development. Applied Pharmaceutical Analysis Conference, Boston, MA September 2008.

Symposium on Drug-Drug Interactions of Biologics. 12th International Conference on Drug-Drug Interactions, Seattle WA, May 2009.

Evening Lecture, Twelfth Annual International Conference on Drug Metabolism and Applied Pharmacokinetics, University of Wisconsin Land O'Lakes Series. Merrimac, WI September 2009

Symposium on Cellular Signaling Mechanisms. International Symposium on Pharmacogenomics and the Regulation of Drug Metabolism Enzymes and Genes. Nanjing, China May 2010.

Symposium on Receptor-Mediated Drug Toxicity and Efficacy. 18th International Symposium on Microsomes and Drug Oxidations. Beijing, China May 2010

Workshop on Effect of Disease on Cytochrome P450 and Membrane Transporters. 16th World Congress of Basic and Clinical Pharmacology (WorldPharma). Copenhagen, Denmark, July 2010.

6th Annual Great Lakes Drug Metabolism and Disposition Group Meeting. Madison, WI, May 2011.

Workshop on Recent Advances in the Investigation of Therapeutic Protein Drug-Drug Interactions: Preclinical and Clinical Approaches. Food And Drug Administration, Silver Springs MD. June 2012.

New England Drug Metabolism Discussion Group. Cambridge, MA December 2012.

Symposium on Mechanistic Role(s) of Cytochrome(s) P450 in Oxidative Stress and Inflammation: New Opportunities for Drug Discovery. Society of Toxicology annual meeting, San Antonio, TX March 2013

Research Triangle Park Drug Metabolism Discussion Group. Durham NC, February 2014

Delaware Valley Drug Metabolism Discussion Group. Langhorne VA, December 2014

Symposium on Inflammation: Effects on Drug Metabolism and Disease Aetiology. 13th European ISSX meeting, Glasgow UK., June 2015.

Second Ling-Nan International Forum on DMPK, Guangzhou, China, 2015

ASPET Symposium: Hear It From the Editors: Navigating the Course Through Journal Submission and Publication. Experimental Biology 2016, San Diego, CA. April 2016.

Drug Discovery Research Institute Symposium, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China, December 2016

Plenary lecture, 2nd Sunrise Symposium for Drug Metabolism, Pharmacokinetics and Dynamics. Xiamen, China, December 2016

ASPET Symposium on Physiological Regulation of Drug Metabolism and (Chair and speaker). Experimental Biology 2017, Chicago, IL.

ASPET Symposium: Hear It From the Editors: Navigating the Course Through Journal Submission and Publication. Experimental Biology 2017, Chicago, IL.

CONSULTATION:

2008-2009 Consultant, Hoffmann LaRoche Inc.2010 Consultant, Johnson & Johnson, Inc.

2010	Consultant, Boehringer-Ingelheim
2010	Consultant, Abbott Laboratories

OUTREACH:

Panelist, National Youth Leadership Forum, Explore STEM Program, Oglethorpe University, July 2014

Panelist, National Youth Leadership Forum, Explore STEM Program, Emory University, July 2015, 2016

Personal Statements Review and Admissions Process Workshop. Georgia Gwinnett College, February 2017

BIBLIOGRAPHY

Original research articles

- 1. Powis G, Cummings J and Morgan E (1979) The Effect of Adrenalectomy upon the Absorption, Distribution and Metabolism of Ethanol in the Rat. *Life Sci.* **21**: 1033-1036. PMID7271897.
- 2. <u>Morgan ET</u>, Devine M and Skett P (1981) Changes in the Rat Hepatic Mixed Function Oxidase System Associated with Chronic Ethanol Vapour Inhalation. *Biochem. Pharmacol.* **30**: 595-600. PMID7271897.
- 3. Koop DR, Morgan ET, Tarr GE and Coon MJ (1982) Purification and Characterization of a Unique Isozyme of Cytochrome P-450 from Liver Microsomes of Ethanol-Treated Rabbits. *J. Biol. Chem.* **257**: 8472-8480. PMID7085677.
- 4. Morgan ET, Koop DR and Coon MJ (1982) Catalytic Activity of Cytochrome P-450 Isolated from Liver Microsomes of Ethanol-Treated Rabbits: Oxidation of Alcohols. *J. Biol. Chem.* **257**: 13951-13957. PMID7142188.
- 5. <u>Morgan ET</u>, Koop DR and Coon MJ (1983) Comparison of Six Rabbit Liver Cytochrome P-450 Isozymes in Formation of a Reactive Metabolite of Acetaminophen. *Biochem. Biophys. Res. Commun.* **112:** 8-13. PMID6838622
- 6. Coon MJ, Koop DR and Morgan ET (1983) Alcohol Oxidation by Isozyme 3a of Liver Microsomal Cytochrome P-450. *Pharmacol., Biochem. Behav.* **18**, suppl. 1: 177-180. PMID6685276.
- 7. <u>Morgan ET</u> and Coon MJ (1984) Effects of Cytochrome <u>b</u>₅ on Cytochrome P-450-Catalyzed Reactions: Studies with Manganese-Substituted Cytochrome <u>b</u>₅. *Drug Metab. Dispos.* **12:** 358-364. PMID6145564.
- 8. MacGeoch C, <u>Morgan ET</u>, Halpert J and Gustafsson, J-Å (1984) Purification, Characterization and Pituitary Regulation of the Sex-Specific Cytochrome P-450 15ß-Hydroxylase from Liver Microsomes of Untreated Female Rats. *J. Biol. Chem.* **254**: 15433-15439. PMID6511799.
- Morgan ET, MacGeoch C and Gustafsson J-Å (1985) Sexual Differentiation of Cytochrome P-450 in Rat Liver. Evidence for a Constitutive Isozyme as the Male-Specific 16α-Hydroxylase. *Mol. Pharmacol.* 27: 471-479. PMID3982392.
- Halpert J, Balfour C, Miller NE, Morgan ET, Dunbar D and Kaminsky LS (1985) Isozyme Selectivity of the Inhibition of Rat Liver Cytochrome P-450 by Chloramphenicol in vivo. Mol. Pharmacol. 28: 290-296. PMID4033629.
- 11. Morgan ET, MacGeoch C and Gustafsson J-Å (1985) Hormonal and Developmental Regulation of Expression of the Hepatic Microsomal Steroid 16α-Hydroxylase Cytochrome P-450 Apoprotein in the Rat. *J. Biol. Chem.* **260**: 11895-11898. PMID3876334.
- MacGeoch C, Morgan ET and Gustafsson J-Å (1985) Hypothalamo-Pituitary Regulation of Cytochrome P-45015ß Apoprotein Levels in Rat Liver. *Endocrinology* 117: 2085-2092. PMID4042976.
- 13. von Bahr C, Birgersson C, Morgan ET, Eriksson O, Goransson M, Spina E and Woodhouse K. (1985) Oxidation of Tricyclic Antidepressant Drugs, Debrisoquine and 7-Ethoxyresorufin by Human Liver Microsomes. *Xenobiotica* **16**: 391-400. PMID3739365.

- 14. Birgersson C, Morgan ET, Jornvall H and von Bahr C. (1986) Purification of a Desmethylimipramine and Debrisoquine Hydroxylating Cytochrome P-450 from Human Liver. *Biochem. Pharmacol.* **35**, 3165-3166. PMID3753522.
- 15. MacGeoch C, Morgan ET, Cordell B and Gustafsson J-Å (1987) Growth Hormone Regulates Expression of Rat Liver Cytochrome P-45015ß at a Pretranslational Level. *Biochem. Biophys. Res. Commun.***143:** 782-788. PMID3494447.
- Morgan ET, Ronnholm M and Gustafsson J-Å (1987) Preparation and Characterization of Monoclonal Antibodies Recognizing Unique Epitopes on Sexually Differentiated Rat Liver Cytochrome P-450 Isozymes. *Biochemistry* 26: 4193-4200. PMID2444248.
- 17. Ström A, Mode A, Zaphiropoulos P, Nilsson A-G, Morgan ET and Gustafsson J-Å (1988) Cloning and Pretranslational Hormonal Regulation of Testosterone 16α-hydroxylase (P-45016α) in Male Rat Liver. *Acta endocrinol.* **118:** 314-320. PMID2455430.
- 18. <u>Morgan ET</u> (1989) Suppression of Constitutive Cytochrome P-450 Gene Expression in Livers of Rats Undergoing an Acute Phase Response to Endotoxin. *Mol. Pharmacol.* **36**: 699-707. PMID2511427.
- 19. Donahue BS and Morgan ET (1990) Effects of Vanadate on Hepatic Cytochrome P-450 Expression in Streptozotocin-diabetic Rats. *Drug Metab. Dispos.* **18:** 519-526. PMID1698138.
- Morgan ET and Norman CA (1990) Pretranslational Suppression of Cytochrome P-450h (IIC11) Gene Expression in Rat Liver After Administration of Interferon Inducers. *Drug Metab. Dispos.* 18: 649-653. PMID1706245.
- 21. Wright K and Morgan ET (1990) Transcriptional and Post-transcriptional Suppression of P450IIC11 and P450IIC12 by Inflammation. *FEBS Lett.* **271**: 59-61. PMID2226815.
- 22. Wright K and Morgan ET (1991) Regulation of P450IIC12 Expression by Interleukin-1α, Interleukin-6 and Dexamethasone. *Mol. Pharmacol.* **39:** 468-474. PMID2017147.
- 23. Donahue BS, Skottner-Lundin A and Morgan ET (1991) Growth Hormone-Dependent and Independent Regulation of Cytochrome P-450 Isozyme Expression in Streptozotocindiabetic Rats. *Endocrinology* **128**: 2065-2076. PMID1706265.
- 24. <u>Morgan ET</u> (1991) Suppression of P450IIC12 Gene Expression and Elevation of Actin Messenger Ribonucleic Acid Levels in the Livers of Female Rats after Injection of the Interferon Inducer Poly rl.poly rC. *Biochem. Pharmacol.* **42:** 51-57. PMID2069598.
- 25. Merrill AH Jr, Wang E, LaRocque R, Mullins RE, Morgan ET, Hargrove JL, Bonkovsky HL and Popova IA (1992) Differences in Glycogen, Lipids, and Enzymes in Livers from Rats Flown on Cosmos 2044. *J. Appl. Physiol.* **73:** 142S-147S. PMID1526942
- 26. <u>Morgan ET</u> (1993) Down-Regulation of Multiple Cytochrome P450 Gene Products by Inflammatory Mediators In Vivo: Independence from the Hypothalamo-Pituitary Axis. *Biochem. Pharmacol.* **45:** 415-419. PMID8435092.
- 27. Ferguson NL, Donahue BS, Tenney KA and Morgan ET (1993) Pretranslational Induction of CYP4A Subfamily Gene Products in Diabetic Rats and Reversal by Oral Vanadate Treatment. *Drug Metab. Dispos.* **21**: 745-746. PMID8104136.
- 28. Morgan ET, Thomas KB, Swanson R, Vales T, Hwang J and Wright K (1994) Selective Suppression of Cytochrome P450 Gene Expression by Interleukins 1 and 6 in Rat Liver. *Biochim. Biophys Acta* **1219:** 475-483. PMID7918645.

- 29. Kraner JC, Morgan ET and Halpert JR (1994) Selective Suppression of Rat Hepatic Cytochrome P450 2C11 by Chloramphenicol. *J. Pharmacol. Exp. Ther.* **270**: 1367-1372. PMID7932191.
- 30. Chen J-Q, Ström A, Gustafsson J-Å and Morgan ET (1995) Suppression of the Constitutive Expression of Cytochrome P-450 2C11 by Cytokines and Interferons in Primary Cultures of Rat Hepatocytes: Comparison with Induction of Acute-Phase Genes and Demonstration that CYP2C11 Promoter Sequences Are Involved in the Suppressive Response to Interleukins 1 and 6. *Mol. Pharmacol.* **47**: 940-947. PMID7538197.
- Chen J-Q, Nikolova-Karakashian M, Merrill AH Jr and Morgan ET (1995) Regulation of Cytochrome P450 2C11 (CYP2C11) Gene Expression by Interleukin-1, Sphingomyelin Hydolysis, and Ceramide in Rat Hepatocytes. *J. Biol. Chem.* 270: 25233-25238. PMID7559661.
- 32. Sewer MB, Koop DR and Morgan ET (1995) Endotoxemia in Rats is Associated with Induction of the P-450 4A Subfamily and Suppression of Several Other Forms of Cytochrome P-450. *Drug Metab. Dispos.* **24:** 401-407. PMID8801054.
- 33. Kraner JC, Morgan ET, Poet TS, Born SL, Burnett VL and Halpert JH (1996) Suppression of Rat Hepatic Microsomal Cytochromes P450 by Cyclophosphamide is Correlated with Plasma Thyroid Hormone Levels and Displays Differential Strain Sensitivity. *J. Pharmacol. Exp. Ther.* **276:** 258-264. PMID8558440.
- 34. Ching KZ, Tenney KA, Chen J-Q and Morgan ET (1996) Suppression of Constitutive Cytochrome P-450 Gene Expression by Epidermal Growth Factor Receptor Ligands in Cultured Rat Hepatocytes. *Drug Metab. Dispos.* **24:** 542-546. PMID8723734.
- 35. Sewer MB, Koop DR and Morgan ET (1997) Differential inductive and suppressive effects of endotoxin and particulate irritants on hepatic and renal cytochrome P-450 expression. *J. Pharmacol. Exp. Ther.* **280:** 1445-1454. PMID9067334.
- 36. Sewer MB and Morgan ET (1997) Nitric oxide independent suppression of P-450 2C11 expression by interleukin-1β and endotoxin in primary rat hepatocytes. *Biochem. Pharmacol.* **54:** 729-737. PMID9310350.
- 37. Iber H, Chen Q, Sewer MB and Morgan ET (1997) Regulation of hepatic cytochrome P450 2C11 by glucocorticoids. *Arch. Biochem. Biophys.* **345:** 305-310. PMID9308903.
- 38. Nikolova-Karakashian M, Morgan ET, Alexander C, Liotta DC and Merrill AH Jr. (1997) Bimodal regulation of ceramidase by interleukin-1 beta Implications for the regulations of cytochrome P450 2C11 (CYP2C11). *J. Biol. Chem.* **272:** 18718-18724. PMID9228043.
- 39. Sewer MB, Barclay TB and Morgan ET (1998) Down-regulation of cytochrome P450 mRNAs and proteins in mice lacking a functional NOS2 gene. *Mol. Pharmacol.* **54:** 273-279. PMID9687568.
- 40. Sewer MB and Morgan ET (1998) Down-regulation of the expression of three major rat liver cytochrome P450s by endotoxin in vivo occurs independently of NO production. *J. Pharmacol. Exp. Ther.* **287**: 352-358. PMID9765356.
- 41. Iber H and Morgan ET (1998) Regulation of hepatic cytochrome P450 2C11 by Transforming Growth Factor-β, Hepatocyte Growth Factor and Interleukin-11. *Drug Metab. Dispos.* **26:** 1042-1044. PMID9763412.
- 42. Barclay TB, Peters JM, Sewer MB, Ferrari L, Gonzalez FJ and Morgan ET (1999)

- Modulation of cytochrome P450 gene expression in endotoxemic mice is tissue-specific and PPARα-dependent. *J. Pharmacol. Exp. Ther.* **290**: 1250-1257. PMID10454501.
- 43. Iber H, Chen Q, Cheng P-Y and Morgan ET (2000) Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-κB binding at the transcription start site. *Arch. Biochem. Biophys.* **377:** 187-194. PMID10775459.
- 44. Mitchell SR, Sewer MB, Kardar SS and Morgan ET (2001) Characterization of CYP4A induction in rat liver by inflammatory stimuli: Dependence on sex, strain and inflammation-evoked hypophagia. *Drug Metab. Dispos.* **29:** 17-22. PMID11124224.
- 45. Cui X, Kawashima H, Barclay TB, Peters JM, Gonzalez FJ, Morgan ET and Strobel HW (2001) Molecular cloning and regulation of expression of two novel mouse CYP4F genes expressed in PPARα deficient mice upon LPS and clofibrate challenges. *J. Pharmacol. Exp. Ther.* **296:** 542-55. PMID11160642.
- 46. Li-Masters T and Morgan ET (2001) Effects of bacterial lipopolysaccharide on phenobarbital-induced CYP2B expression in mice. *Drug Metab. Dispos.* **29:** 252-257. PMID11181491.
- 47. Iber H, Li-Masters T, Chen Q, Yu S and Morgan ET (2001) Regulation of hepatic cytochrome P450 2C11 via cAMP: Implications for down-regulation in diabetes, fasting and inflammation. *J. Pharmacol. Exp. Ther.* **297**: 174-180. PMID11259542.
- 48. Ferrari L, Peng N, Halpert JR and Morgan ET (2001) Role of Nitric Oxide in Down-Regulation of CYP2B1 protein, but not RNA, in primary cultures of rat hepatocytes. *Mol. Pharmacol.* **60**: 209-216. PMID11408616.
- 49. Li-Masters T and Morgan ET (2002) Down-regulation of phenobarbital-induced cytochrome P4502B mRNAs and proteins by endotoxin in mice: independence from NO production by inducible nitric oxide synthase *Biochem. Pharmacol.* **64:** 1703-1711. PMID12445859.
- 50. Cheng P-Y, Wang M and Morgan ET (2003) Rapid transcriptional suppression of rat cytochrome P450 genes by endotoxin treatment and its inhibition by curcumin. *J. Pharmacol. Exp. Ther.* **307**:1205-1212. PMID14557382.
- 51. Kalsotra A, Cui X, Antonovic L, Robida AM, Morgan ET and Strobel HW (2003) Inflammatory prompts produce isoform-specific changes in the expression of leukotriene B4 ω-hydroxylases in rat liver and kidney. *FEBS Lett.* **555**: 236-242. PMID14644421.
- 52. Richardson TA and Morgan ET (2005) Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice. *J. Pharmacol. Exp. Ther.* **314:** 703-709. PMID15860574.
- 53. Jaworski JN, Francis DD, Brommer CL, <u>Morgan ET</u> and Kuhar MJ (2005) Effects of early maternal separation on ethanol intake, GABA receptors and metabolizing enzymes in adult rats. *Psychopharmacology* **181**: 8-15. PMID1580234.
- 54. Richardson TA, Sherman S, Antonovic L, Kardar SS, Strobel HW, Kalman D and Morgan ET (2006) Hepatic and renal cytochrome P450 gene regulation during *Citrobacter rodentium* infection in wildtype and toll-like receptor 4 mutant mice. *Drug Metab. Dispos.* **34**: 354-360. PMC1382008; PMID16339354.
- 55. Richardson TA, Sherman S, Kalman D and Morgan ET (2006) Expression of UDP-glucuronosyltransferase mRNAs during inflammation and infection in mouse liver and kidney. *Drug Metab. Dispos.* **34:** 351-353. PMC1403152; PMID16339353.
- 56. Sidell N, Kirma N, Morgan ET, Nair H and Tekmal RR (2007) Inhibition of estrogen-induced mammary tumor formation in MMTV-aromatase transgenic mice by 4-chlorophenylacetate. *Cancer Letters* **251**: 302-310. PMC1940067; PMID17215075.

- 57. Kalsotra A, Anakk S, Brommer CL, Kikuta Y, Morgan ET and Strobel HW. (2007) Catalytic characterization and cytokine mediated regulation of cytochrome P450 4Fs in rat hepatocytes. *Arch. Biochem. Biophys.* **461:** 104-112. PMC2574503; PMID17418803.
- 58. Aitken AE and Morgan ET (2007) Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P4502C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes. *Drug Metab. Dispos.* **35:** 1687-1693. PMC2171046; PMID17576808.
- 59. Lee C-M, Kim B-Y, Li L and Morgan ET (2008) Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins. *J. Biol. Chem.* **283**: 889-898. e-pub Nov 2007. * subject of **Spotlight** article in Chem. Res Toxicol (2008) 21: 7-8. PMC2185771; PMID17993647
- 60. Chen C, Shah Y, Morimura K, Krausz KW, Miyazaki M, Richardson TA, Morgan ET, Ntambi, JM, Idle JR and Gonzalez FJ (2008) Metabolomics reveals that hepatic stearoyl-CoA desaturase down-regulation exacerbates inflammation and acute colitis. *Cell Metab.* 7: 135-147. PMC2276699; PMID18249173.
- 61. Aitken AE, Lee C-M and Morgan ET (2008) Roles of Nitric Oxide in Inflammatory Down-Regulation of Human Cytochromes P450. Free Radic. Biol. Med. 44: 1161-1168. PMC2346593; PMID18206661.
- 62. Chaluvadi MR, Kinloch RD, Nyagode BA, Richardson TA, Raynor MJ, Sherman M, Antonovic L, Strobel HW, Dillehay DL and Morgan ET (2009) Regulation of Hepatic Cytochrome P450 Expression in Mice with Intestinal or Systemic Infections of Citrobacter rodentium. Drug Metab. Dispos. 37: 366-374. PMC2631938; PMID18971315.
- 63. Chaluvadi MR, Nyagode BA, Kinloch RD and Morgan ET (2009) TLR4-Dependent and Independent Regulation of Hepatic Cytochrome P450 in Mice with Chemically-Induced Inflammatory Bowel Disease. *Biochem. Pharmacol.* 77: 464-471. PMC2932663; PMID19027721.
- 64. Zhang J, Chaluvadi M, Reddy R, Motika MS, Richardson TA Cashman JR and Morgan ET (2009) Hepatic flavin-containing monooxygenase gene regulation in different mouse inflammation models. *Drug Metab. Dispos.* **37:** 462-468. PMC2680514; PMID19088265.
- 65. Lee C-M, Pohl J and Morgan ET (2009) Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures. *Drug Metab. Dispos.* **37**: 865-872. PMC2680532; PMID19171675.
- 66. Nyagode BA, Lee C-M and Morgan ET (2010) Modulation of Hepatic Cytochrome P450s by *Citrobacter rodentium* Infection in Interleukin-6- and Interferon-γ-null Mice. *J. Pharmacol. Exp. Ther.* **335:** 480-488. e-pub August 18, 2010. PMC3202470; PMID20719939
- 67. Lee C-M, Kumar V, Riley RI and Morgan ET (2010) Metabolism and action of proteasome inhibitors in primary human hepatocytes. *Drug Metab. Dispos.* **38:** 2166-2172. e-pub September 13, 2010. PMC2993455; PMID20837660.
- 68. Kinloch RD, Lee C-M, van Rooijen N and Morgan ET (2011) Selective Role for Tumor Necrosis Factor-α, but Not Interleukin-1 or Kupffer Cells, in Down-Regulation of CYP3A11 and CYP3A25 in Livers of Mice Infected with a Noninvasive Intestinal Pathogen. *Biochem. Pharmacol.* 82: 312-321. e-pub June 23, 2011 PMC3124565; PMID21570957.
- 69. Sun H, Lee C-M, Tripathi S, Kim K-B and Morgan ET (2012) Nitric oxide-dependent CYP2B1 degradation is potentiated by a cytokine-regulated pathway and utilizes the immunoproteasome subunit LMP2. *Biochem. J.* **445**: 377-382. e-pub May 22. Doi 10.1042/BJ20120820. PMC3557507; PMID22612225.

- 70. Nyagode BA, Watkins WJ, Kinloch RD and Morgan ET (2012) Selective Modulation of Hepatic Cytochrome P450 and Flavin Monooxygenase 3 Expression during Citrobacter rodentium Infection in Severe Combined Immune-Deficient Mice *Drug Metab Dispos* **40**: 1894-1899 PMC3463824; PMID22745333.
- 71. Lee C-M, Lee B-M, Arnold SL, Isoherranen N and Morgan, ET (2013) Nitric oxide and interleukin-1β stimulate the proteasome-independent degradation of the retinoic acid hydroxylase CYP2C22 in primary rat hepatocytes. *J. Pharmacol. Exp. Ther.* **348:** 141-152. E-pub October 21, doi:10.1124/jpet.113.209841 PMC3868880; PMID24144795.
- 72. Mimche SM, Nyagode BA, Merrell MD, Lee C-M, Prasanphanich NS, Cummings RD and Morgan ET (2014) Hepatic cytochrome P450s, phase II enzymes and nuclear receptors are down-regulated in a Th2 environment during *Schistosoma mansoni* infection. *Drug Metab Dispos* **42**: 134-40. E-pub October 25, 2013, doi:10.1124/dmd.113.054957 PMC3876789; PMID24163175.
- 73. Nyagode BA, Williams I and Morgan ET (2014) Altered inflammatory responses to *Citrobacter rodentium* infection, but not to bacterial lipopolysaccharide, in mice lacking the *Cyp4a10* and *Cyp4a14* genes. *Inflammation*, 37:893-907 E-pub Jan 11, 2014. Doi 10.1007/s10753-013-9809-6. PMC4035451: PMID24413902.
- 74. Merrell MD, Nyagode BA, Clarke JD, Cherrington NJ and Morgan ET (2014) Selective and cytokine-dependent regulation of hepatic transporters and bile acid homeostasis during infectious colitis in mice. Drug Metab Dispos 42: 596-602 E-pub Dec 30, 2013, doi:10.1124/dmd.113.055525. PMC396589; PMID24378326.
- 75. Nyagode BA, Janhangardi R, Merrell MD, Tansey M and Morgan ET (2014) Selective effects of a therapeutic protein targeting tumor necrosis factor-alpha on cytochrome P450 regulation during infectious colitis: Implications for disease-dependent drug-drug interactions. *Pharmacol Res Perspect* 2(1):e00027. PMC3972819; PMID24707356.
- 76. Mimche PN, Brady LM, Bray CF, Thapa M, McDermott CD, King TP, Quicke K, Lee CM, Mimche SM, Grakoui A Morgan ET and Lamb TJ (2015) The receptor tyrosine kinase EphB2 promotes hepatic fibrosis in mice. *Hepatology* 62: 900-914 E-pub Mar 17, 2015 doi: 10.1002/hep.27792. PMCID: 5459176; PMID 25784101.
- 77. Lee C-M, Tripathi S and Morgan ET (2017) Nitric oxide-regulated proteolysis of human CYP2B6 via the ubiquitin-proteasome system. *Free Radic. Biol. Med.* E-pub April 17, 2017. Doi 10.1016/j.freeradbiomed.2017.04.015

Refereed review articles

- Morgan ET and Gustafsson J-Å (1987) Sex-Specific Isozymes of Cytochrome P-450. Steroids 49: 213-245. PMID3331849.
- Morgan ET, Nikolova-Karakashian M, Chen J-Q and Merrill AH Jr (1996) Sphingolipid-Dependent Signaling in Regulation of Cytochrome P450 Expression. *Methods Enzymol.* 272: 381-388. PMID8791797.

- 3. <u>Morgan ET</u> (1997) Regulation of cytochromes P450 during inflammation and infection. *Drug Metab. Rev.* **29:** 1129-1188. PMID9421688.
- 4. <u>Morgan ET</u> (2001) Regulation of cytochrome P450 by inflammatory mediators: Why and How? *Drug Metab. Dispos.* **29:** 207-212. PMID11181485.
- 5. Cheng P-Y and Morgan ET (2001) Hepatic Cytochrome P450 Regulation in Disease States. *Curr. Drug Metab.* **2:** 165-183. PMID11469724.
- 6. Aitken AE, Richardson TA and Morgan ET (2006) Regulation of Drug Metabolizing Enzymes and Transporters in Inflammation. *Ann. Rev. Pharmacol. Toxicol.*, **46**: 123-149. PMID1642901.
- 7. <u>Morgan ET</u> (2009) Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. *Clin Pharmacol. Therap.* **85:** 434-438. PMCID3139248; PMID19212314.
- 8. Harvey RD and Morgan ET (2014) Cancer, inflammation, and Therapy: Effects on Cytochrome P450-Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents. *Clin Pharmacol. Therap.* **96**: 449-457. PMID 24987833.

Book chapters, monographs and symposium reports

- 1. Coon MJ, Koop DR, Persson AV and Morgan ET (1980) Inducible and Constitutive Isozymes of Microsomal Cytochrome P-450. In *Biochemistry, Biophysics and Regulation of Cytochrome P-450.* (J.-Å. Gustafsson et al., eds.) pp. 7-15, Elsevier/North Holland.
- Coon MJ, Black SD, Koop DR, Morgan ET and Persson AV (1981) Structure and Function of NADPH-cytochrome P-450 Reductase and of Isozymes of Cytochrome P-450. In Mitochondria and Microsomes (L.P. Lee et al., eds.) pp. 701-728, Addison-Wesley Publishing Co., London.
- 3. Koop DR, Morgan ET and Coon MJ (1982) Purification of Multiple Forms of Rabbit Hepatic Cytochrome P-450. In *Microsomes, Drug Oxidations and Drug Toxicity* (Sato, R. and Kato, R., eds.) pp. 85-86, Wiley-Interscience, New York.
- 4. Coon MJ, Black SD, Koop DR, Morgan ET and Tarr GE (1982) Structural and Catalytic Studies with Purified Microsomal Enzymes. In *Microsomes, Drug Oxidations and Drug Toxicity* (Sato, R. and Kato, R., eds.) pp. 13-23, Wiley-Interscience, New York.
- 5. Koop DR and Morgan ET (1982) Spectral and Catalytic Properties of Ethanol-Inducible Cytochrome P-450 Isozyme 3a. In Cytochrome P-450. Biochemistry, Biophysics and Environmental Implications (Hietanen, E., Laitinen, M. and Hanninen, O., eds.) pp. 269-275, Elsevier/North Holland
- 6. Gustafsson J-Å, MacGeoch C and Morgan ET (1985) Isolation, Characterization and Regulation of Sex-Specific Isozymes of Cytochrome P-450 Catalyzing 15β- Hydroxylation of Steroid Sulphates and 16α-Hydroxylation of 4-Androstene-3,17-dione. In *Microsomes and Drug Oxidations* (A.R. Boobis et al, eds.) pp. 55-62. Taylor and Francis, London.
- 7. MacGeoch C, Morgan ET and Gustafsson J-Å (1985) Hormonal Regulation of Sexually Differentiated Cytochrome P-450 Isozymes in Rat Liver. In *Cytochrome P-450, Biochemistry, Biophysics and Induction* (L. Vereczkey and K. Magyar, eds.) pp. 235-238. Akademial Kiado, Budapest.
- 8. MacGeoch C, Morgan ET and Gustafsson J-A (1987) Hormonal Regulation of Sexually Differentiated Isozymes of Cytochrome P-450 in Rat Liver. In *Gene Regulation by Steroid Hormones III* (A. Roy and J. Clark, eds.) pp. 247-273. Springer-Verlag, New York.

- Mode A, Zaphiropoulos P, Strom A, MacGeoch C, Moller C, Morgan E and Gustafsson J-Å (1987) Complete Sequence and Hormonal Regulation of Cytochrome P-450 Isozymes
 15ß and 16α. In Microsomes and Drug Oxidations. Proceedings of the 7th International Symposium. (J.Miners et al, eds.) pp. 131-139. Taylor and Francis, London.
- 10. Morgan ET and Gustafsson J-Å (1989) The Hormonal and Molecular Basis of Sexually Differentiated Hepatic Drug and Steroid Metabolism in the Rat. In *Frontiers in Biotransformation Vol.1*. Basis and Mechanisms of Regulation of Cytochrome P-450. (K. Ruckpaul and H. Rein, eds.) pp. 176-194. Akademie-Verlag, Berlin.
- Morgan ET, Sewer MB, Iber H, Gonzalez FJ, Lee Y-H, Tukey RH, Okino S, Vu T, Chen Y-H, Sidhu JS and Omiecinski CJ (1998) Physiological and Pathophysiological Regulation of Cytochrome P450. *Drug Metab. Dispos.* 26: 1232-1240. PMID9860933.
- 12. Iber H, Sewer MB, Barclay TB, Mitchell SR, Li T and Morgan ET (1999) Modulation of drug metabolism in infectious and inflammatory diseases. *Drug Metab. Rev.* **31:** 29-41. PMID10065364.
- 13. Merrill AH Jr, Morgan ET, Nikolova-Karakashian M and Stewart J (1999) Sphingomyelin hydrolysis and regulation of the expression of the gene for cytochrome P450. *Biochem. Soc. Trans.* **27**: 383-387. PMID10917607.
- 14. Merrill AH Jr, Nikolova-Karakashian M, Schmelz EM, Morgan ET and Stewart J (1999) Regulation of cytochrome P450 expression by sphingolipids. *Chem. Phys. Lipids* **102**: 131-139. PMID11001567.
- Morgan ET, Ullrich V, Daiber A, Schmidt P, Takaya N, Shoun H, McGiff JC, Oyekan A, Hanke CJ, Campbell WB, Park C-S, Kang J-S, Yi H-G, Cha Y-N, Mansuy D and Boucher J-L (2001) Cytochromes P450 and Flavin Monooxygenases – Targets and Sources of Nitric Oxide. *Drug Metab. Dispos.* 29: 1366-1376. PMID11602511.
- 16. <u>Morgan ET</u>, Li-Masters T and Cheng, P-Y (2002) Mechanisms of Cytochrome P450 Regulation by Inflammatory Mediators *Toxicology* **181-182**: 207-210. PMID12505312.
- 17. Cui X, Kalsotra A, Robida AM, Matzilevich D, Moore AN, Boehme CL, Morgan ET, Dash PK and Strobel HW (2003) Expression of cytochromes P450 4F4 and 4F5 in infection and injury models of inflammation. *Biochim. Biophys. Acta* **1619**: 325-331.
- 18. Riddick DS, Lee C, Bhathena A, Timsit YE, Cheng P-Y, Morgan ET, Prough RA, Ripp SL, Michael Miller KK, Jahan A and Chiang JYL (2004) Transcriptional suppression of cytochrome P450 genes by endogenous and exogenous chemicals. *Drug Metab. Dispos.* **32**: 367-375. PMID15039287.
- Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R and Sinal CJ (2008) Regulation of Drug Metabolizing Enzymes in Infection, Inflammation and Cancer. Drug Metab. Dispos. 36: 205-216. PMID18218849.
- Morgan ET, Lee C-M and Nyagode BA (2012) Regulation of Drug Metabolizing Enzymes in Infection, Inflammation and Cancer. In *Encyclopedia of Drug Metabolism and Interactions*, vol. 8 (AV Lyubimov, ed.). Wiley DOI: 10.1002/9780470921920.edm089
- 21. <u>Morgan ET</u> (2017) Regulation of Drug Metabolizing Enzymes and Drug Metabolism by Inflammatory Responses. In Drug Metabolism in Diseases (W. Xie, ed.) Academic Press, Elsevier, Amsterdam. ISBN: 978-0-12-802949-7
- 22. Yu A-M, Ingelman-Sundberg M, Cherrington N, Aleksunes L, Zanger UM, Xie W, Jeong H, Morgan E, Turnbaugh PJ, Klaassen CD, Redinbo M, Hao P, Waxman DJ, Wang L and Zhong, X-B. (2017). A meeting report of the 21st International Symposium on Microsomes

and Drug Oxidations (MDO). Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, IncRNAs, gut microbiota, and diseases. Acta Pharmaceutica Sinica part B, in press.

Digital Media

 Morgan, ET (2006) Effect of physiological factors and disease on drug metabolism. in Drug Metabolizing Enzymes (A.K. Daly, ed.), Drug Metabolizing Enzymes: Fundamentals, Study Methods, Recent Advances and Clinical Significance, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (online at http://www.hstalks.com/lib.php?t=HST9.9 03 1 4&s=Morgan)

Editorials and Letters to the Editor

- 1. Byrd DM 3rd, Allen DO, Beamer RL, Besch HR Jr, Bylund DB, Doull J, Fleming WW, Fries A, Guengerich FP, Hornbrook R, Lasagna L, Lum BK, Michaelis EK, Morgan ET, Poland A, Rozman KK, Smith JB, Swanson HI, Waddell JW, Wilson JD (1998) The dose-response model for dioxin. *Risk Anal.* **18:** 1-2. PMID9556441.
- 2. Morgan ET (2005) A. role for one or more p450 enzymes in the response to sepsis. *Crit. Care Med.* **33:** 268-269. PMID15644701.
- 3. Morgan ET (2012) Editorial. *Drug Metab. Dispos.* **40:** 413. PMID22337621